Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas

SIMPLE SUMMARY: Immunotherapy using antibodies against programmed cell death protein 1 (PD-1) or its ligand PD-L1 can restore host antitumor immunity in many types of cancer. Hence, PD-1/PD-L1 blockade therapy has become the standard treatment for various cancer types in the last decade. However, ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuya, Hiroo, Suzumiya, Junji, Kimura, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670854/
https://www.ncbi.nlm.nih.gov/pubmed/38001659
http://dx.doi.org/10.3390/cancers15225399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670854/
https://www.ncbi.nlm.nih.gov/pubmed/38001659
http://dx.doi.org/10.3390/cancers15225399

Ejemplares similares